.jpg)
.png)
Top Stories
Experiencing side effects such as muscle-related pain or weakness was the top reason why patients stopped taking statins, according to results from a large survey. MedPage Today - June 22, 2012
Pursuant to the advice of the Chapter of the National Lipid Association, the following updates to the Bylaws are proposed to the NLA membership for adoption at the NLA Business Meeting on May 18, 2019. The purpose of the update is to restore the position of the at-large directors on the chapter... more
On Dec. 13, the European Medicines Agency announced that it failed to grant marketing approval for Kynamro (mipomersen sodium) due to concerns about its side effects. Kynamro has been in the Sanofi/Isis Pharmaceuticals pipeline as a therapy intended to treat homozygous FH. The drug is under... more
Following a June 2015 recommendation by the U.S Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee, the FDA has approved alirocumab for patients on maximally tolerated statin therapy with heterozygous familial hypercholesterolemia (HeFH) or with clinical... more
JACKSONVILLE, Fla. (April 12, 2019) — The 2019 National Lipid Association Nominating Committee released its annual report and recommendations on Monday. Chaired by NLA Immediate Past President James A. Underberg, MD, MS, FNLA, the committee compiled a list of recommended candidates to... more
Following an October 2012 recommendation by the U.S. FDA's Endocrinologic and Metabolic Drugs Advisory Committee, the FDA has approved lomitapide for patients with homozygous FH. Lomitapide, known by the brand name Juxtapid, is produced by Aegerion Pharmaceuticals. Results from the company... more
Following a June 2015 recommendation by the U.S Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee, the FDA has approved evolocumab for use in addition to diet and maximally-tolerated statin therapy in adult patients with heterozygous familial... more
MIAMI, Fla. – (May 16, 2019) – The NLA has released a statement paper that provides updated guidance to clinicians to help identify patient groups in whom treatment with PCSK9 monoclonal antibodies (mAbs) provides a reasonable value. While initial pricing of... more
A comprehensive new review on how to treat high cholesterol and other blood lipid problems suggests that intensive treatment with high doses of statin drugs is usually the best approach. Ideas, Inventions And Innovations Blog - October 15, 2012
Interim results from the ongoing ORION-3 study that examines the long-term safety and efficacy of small interfering RNA (siRNA) therapy drug inclisiran were shared today during the National Lipid Association’s (NLA) 2019 Scientific Sessions late-breaking abstract session. Inclisiran, the first... more